This page shows the latest Renflexis news and features for those working in and with pharma, biotech and healthcare.
aggressive approach to pricing Renflexis, which is the first US biosimilar to arise out of their 2013 collaboration. ... alleging patent infringement by the biosimilars, claiming it has IP protecting Remicade out to 2027, and filed a lawsuit to try to
competition from Pfizer's Inflectra, Mundipharma's Remsima and Samsung Bioepis' Renflexis/Flixabi.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Notably the biosimilar Renflexis (infliximab-abda) achieved a 70-80% price reduction to its reference product in both Norway and Denmark.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...